These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 32285615)

  • 1. Effect of nintedanib on non-small cell lung cancer in a patient with idiopathic pulmonary fibrosis: A case report and literature review.
    Shiratori T; Tanaka H; Tabe C; Tsuchiya J; Ishioka Y; Itoga M; Taima K; Takanashi S; Tasaka S
    Thorac Cancer; 2020 Jun; 11(6):1720-1723. PubMed ID: 32285615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Remarkable response of non-small cell lung cancer to nintedanib treatment in a patient with idiopathic pulmonary fibrosis.
    Kai Y; Matsuda M; Fukuoka A; Hontsu S; Yamauchi M; Yoshikawa M; Muro S
    Thorac Cancer; 2021 May; 12(9):1457-1460. PubMed ID: 33742758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nintedanib allows retreatment with atezolizumab of combined non-small cell lung cancer/idiopathic pulmonary fibrosis after atezolizumab-induced pneumonitis: a case report.
    Yamakawa H; Oba T; Ohta H; Tsukahara Y; Kida G; Tsumiyama E; Nishizawa T; Kawabe R; Sato S; Akasaka K; Amano M; Kuwano K; Matsushima H
    BMC Pulm Med; 2019 Aug; 19(1):156. PubMed ID: 31438923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment Rationale and Design for J-SONIC: A Randomized Study of Carboplatin Plus Nab-paclitaxel With or Without Nintedanib for Advanced Non-Small-cell Lung Cancer With Idiopathic Pulmonary Fibrosis.
    Otsubo K; Kishimoto J; Kenmotsu H; Minegishi Y; Ichihara E; Shiraki A; Kato T; Atagi S; Horinouchi H; Ando M; Kondoh Y; Kusumoto M; Ichikado K; Yamamoto N; Nakanishi Y; Okamoto I
    Clin Lung Cancer; 2018 Jan; 19(1):e5-e9. PubMed ID: 28687482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis.
    Schmid U; Liesenfeld KH; Fleury A; Dallinger C; Freiwald M
    Cancer Chemother Pharmacol; 2018 Jan; 81(1):89-101. PubMed ID: 29119292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial.
    Otsubo K; Kishimoto J; Ando M; Kenmotsu H; Minegishi Y; Horinouchi H; Kato T; Ichihara E; Kondo M; Atagi S; Tamiya M; Ikeda S; Harada T; Takemoto S; Hayashi H; Nakatomi K; Kimura Y; Kondoh Y; Kusumoto M; Ichikado K; Yamamoto N; Nakagawa K; Nakanishi Y; Okamoto I
    Eur Respir J; 2022 Dec; 60(6):. PubMed ID: 35361630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets.
    Ballester B; Milara J; Cortijo J
    Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30704051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nintedanib: first global approval.
    McCormack PL
    Drugs; 2015 Jan; 75(1):129-39. PubMed ID: 25430078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of chemotherapy for advanced non-small cell lung cancer with idiopathic pulmonary fibrosis.
    Watanabe N; Taniguchi H; Kondoh Y; Kimura T; Kataoka K; Nishiyama O; Kondo M; Hasegawa Y
    Respiration; 2013; 85(4):326-31. PubMed ID: 23171837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
    Reck M; Kaiser R; Mellemgaard A; Douillard JY; Orlov S; Krzakowski M; von Pawel J; Gottfried M; Bondarenko I; Liao M; Gann CN; Barrueco J; Gaschler-Markefski B; Novello S;
    Lancet Oncol; 2014 Feb; 15(2):143-55. PubMed ID: 24411639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lung Cancer in Patients with Severe Idiopathic Pulmonary Fibrosis: Critical Aspects.
    Bargagli E; Bonti V; Ferrari K; Rosi E; Bindi A; Bartolucci M; Chiara M; Voltolini L
    In Vivo; 2017; 31(4):773-777. PubMed ID: 28652456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nintedanib plus Chemotherapy for Small Cell Lung Cancer with Comorbid Idiopathic Pulmonary Fibrosis.
    Ikeda S; Ogura T; Kato T; Kenmotsu H; Agemi Y; Tokito T; Ito K; Isomoto K; Takiguchi Y; Yoneshima Y; Yokoyama T; Harada T; Tanzawa S; Kobayashi N; Iwasawa T; Misumi T; Okamoto H
    Ann Am Thorac Soc; 2024 Apr; 21(4):635-643. PubMed ID: 38364204
    [No Abstract]   [Full Text] [Related]  

  • 13. Nintedanib for the treatment of idiopathic pulmonary fibrosis.
    Varone F; Sgalla G; Iovene B; Bruni T; Richeldi L
    Expert Opin Pharmacother; 2018 Feb; 19(2):167-175. PubMed ID: 29327616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Effects and Adverse Events of Nintedanib Therapy in Idiopathic Pulmonary Fibrosis Patients with Functionally Advanced Disease.
    Barczi E; Starobinski L; Kolonics-Farkas A; Eszes N; Bohacs A; Vasakova M; Hejduk K; Müller V
    Adv Ther; 2019 May; 36(5):1221-1232. PubMed ID: 30877478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Administration of nintedanib after discontinuation for acute exacerbation of idiopathic pulmonary fibrosis: a case report.
    Ikeda S; Sekine A; Baba T; Yamakawa H; Morita M; Kitamura H; Ogura T
    BMC Pulm Med; 2016 Mar; 16():38. PubMed ID: 26940352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and effectiveness of pirfenidone combined with carboplatin-based chemotherapy in patients with idiopathic pulmonary fibrosis and non-small cell lung cancer: A retrospective cohort study.
    Yamamoto Y; Yano Y; Kuge T; Okabe F; Ishijima M; Uenami T; Kanazu M; Akazawa Y; Yamaguchi T; Mori M
    Thorac Cancer; 2020 Nov; 11(11):3317-3325. PubMed ID: 32986306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Research Progress on Pathogenic Mechanism and Potential Therapeutic Drugs of 
Idiopathic Pulmonary Fibrosis Complicated with Non-small Cell Lung Cancer].
    Xiao T; Bao J; Liu X; Huang H; Zhou H
    Zhongguo Fei Ai Za Zhi; 2022 Oct; 25(10):756-763. PubMed ID: 36167462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful Concomitant Therapy with Pirfenidone and Nintedanib in Idiopathic Pulmonary Fibrosis: A Case Report.
    Hagmeyer L; Treml M; Priegnitz C; Randerath WJ
    Respiration; 2016; 91(4):327-32. PubMed ID: 27073887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary Hypertension Exacerbated by Nintedanib Administration for Idiopathic Pulmonary Fibrosis.
    Shimomura I; Abe M; Li Y; Tsushima K; Sakao S; Tanabe N; Ikusaka M; Tatsumi K
    Intern Med; 2019 Apr; 58(7):965-968. PubMed ID: 30568123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nintedanib: A Review of Its Use as Second-Line Treatment in Adults with Advanced Non-Small Cell Lung Cancer of Adenocarcinoma Histology.
    Dhillon S
    Target Oncol; 2015 Jun; 10(2):303-10. PubMed ID: 25894578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.